The Gene That Lets Pancreatic Cancer Ignore Chemotherapy

Ask any oncologist which cancer they'd least want to treat and pancreatic cancer comes up fast. Less than 8% of patients are still alive five years after diagnosis. Chemotherapy helps — until, in most cases, it abruptly stops helping. Researchers at Amity University in Noida and the Regional Centre for Biotechnology in Faridabad think they've found a big part of why. A molecular switch called SNHG10, they argue in Cell Death Discovery, is quietly running the show — fuelling tumor growth and, crucially, teaching cancer cells to shrug off the drugs that should be killing them.

The Cancer That Beats Almost Every Drug We Have

Here's the brutal reality of pancreatic cancer: by the time most people feel sick enough to see a doctor, the cancer has usually already spread. There's no reliable early blood test. Symptoms — vague abdominal pain, maybe some weight loss — are easy to mistake for something far less serious. So when treatment finally starts, doctors are almost always playing catch-up. The go-to drug is gemcitabine, a chemotherapy that's been around since the 1990s. It does work. Just not for long. The tumor adapts, and then it doesn't work at all. That window between "working" and "not working" is what this research is trying to widen — or ideally, to keep open indefinitely.

A Hidden Player Nobody Was Watching

SNHG10 wasn't a total unknown. It had turned up in studies on leukemia, gastric cancer, glioma. But the pancreas? Nobody had really looked. The Amity team went digging through The Cancer Genome Atlas — a massive public database of tumour genetic data — and compared 179 pancreatic cancer samples against 171 healthy pancreatic samples. SNHG10 was consistently higher in the cancer tissue. Not just a little higher. And the more advanced the tumour stage, the higher the SNHG10 reading climbed. That pattern held up when they tested actual cancer cell lines in the lab too — six out of seven pancreatic cancer lines showed elevated SNHG10. The seventh, a line called MIA PaCa-2, didn't. Nobody's sure why yet, and that oddity deserves a closer look.

How Does SNHG10 Actually Control Cancer Growth?

This part genuinely surprised the researchers. SNHG10 isn't flipping a single switch — it's holding down a whole control board at once. When they used molecular tools called antisense oligonucleotides to silence it (think of these as tiny decoys that sneak into cells and gag the gene), cancer cells stopped multiplying as quickly, couldn't move as easily, and started dying. The mechanism runs like a chain: SNHG10 normally keeps a small molecule called miR-150-5p locked up and unable to work. Free that molecule — which is what happens when SNHG10 goes quiet — and it immediately targets a protein called VEGF-A, which tumors need to build their blood supply. No blood supply, no food for the tumour. But it doesn't stop there. Silencing SNHG10 also dialled down five other well-known cancer signals — EGFR, AKT, ERK1/2, mTOR, c-MET — all in one go. One gene. Five pathways. That's unusual, and it's exactly why this finding is drawing attention.

What This Means for Patients Whose Treatment Has Stopped Working

To study drug resistance, the team had to first create it — which took eight months of gradually feeding cancer cells higher and higher doses of gemcitabine until the cells stopped caring. The result was striking. Resistant PANC-1 cells needed nearly 20 times more drug to achieve the same effect as the original cells. They also looked different — elongated, spiky, built for invasion rather than staying put. Classic resistance behaviour. SNHG10 levels in those cells? Way up. Then came the crucial test: silence SNHG10 in the resistant cells and see what happens. The sensitivity to gemcitabine came back. Not partially — back. Tumours in mice shrank over 30 days of treatment with no liver damage detected, which matters a lot if you're ever going to use something like this in a person. Healthy pancreatic cells, for what it's worth, were completely unaffected by the SNHG10 silencing. That's an early but meaningful safety signal.

The Questions Researchers Still Need to Answer

Let's be clear about what this isn't. It's a mouse study. Promising mouse studies fail in human trials all the time — that's not pessimism, it's just the history of cancer research. The mice used here were NOD-SCID, a strain bred without working immune systems, which means nobody knows yet how SNHG10 silencing would interact with a real human immune response. That's a big unknown. Delivering the silencing molecule reliably to pancreatic tumour cells in a living person is also a genuine hard problem — the pancreas is not an easy organ to reach. And that one cell line, MIA PaCa-2, that didn't fit the pattern? That needs explaining before anyone draws too firm a conclusion. Still — the consistency across multiple cancer lines, two separate silencing methods, and an animal model is hard to dismiss. This is a result that earns a serious follow-up.

• One gene, five pathways — Silencing SNHG10 knocked down five separate cancer-driving signals at once, which is rare and suggests this gene sits unusually high up in the tumour's command structure.
• Resistance can be reversed — Cancer cells that needed nearly 20 times more gemcitabine to die went back to normal sensitivity after SNHG10 was blocked — a direct finding for patients whose treatment has already failed.
• Healthy cells stayed healthy — The silencing had no detectable effect on normal pancreatic cells, which is an early but important signal that targeting SNHG10 might not cause the collateral damage that makes so many cancer treatments so brutal.

"This study comprehensively uncovers the potential role and molecular mechanism of SNHG10 in pancreatic carcinoma — and may be helpful for the development of new strategies for PDAC treatment." — Pandya, Singh, Garg et al., Cell Death Discovery, 2026.

Advertisement